Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
200 shown of 8,565 total abstracts
  1. Abstract 13612026-04-03 · 13:00 CT · S100A
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-384
    F. Andre, M. Krop, S. Antonia, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 12352026-04-04 · 21:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-211
    T. Mok, N. Rizvi · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 16402026-04-04 · 20:45 CT · S100A
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M. Reck, R. Herbst, C. Robert · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 16082026-04-02 · 14:00 CT · S406
    Quality of life outcomes with Tecentriq in patients with TNBC
    C. Saura, S. Peters, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 15142026-04-03 · 15:00 CT · S100A
    MONALEESA-541: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    J. Brahmer, N. Rizvi · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 11982026-04-05 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-784 study)
    S. Antonia, N. Rizvi, P. Schmid, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 14612026-04-04 · 19:00 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    M.C. Garassino, S. Modi · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 12012026-04-04 · 20:30 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-270 study)
    C. Robert, L. Paz-Ares · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 12402026-04-01 · 15:45 CT · S100A
    MONARCH-292: Verzenio (abemaciclib) 1L in HR+ breast cancer
    M. Krop, R. Herbst · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract e120092026-04-05 · 16:30 CT · Arie Crown Theater
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    A. Spira, M.C. Garassino, M. Krop, et al. · Institut Gustave Roussy
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  11. Abstract 11082026-04-01 · 18:15 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    P. Schmid, S. Antonia, E. Winer · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 13752026-04-03 · 13:45 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-796
    M.C. Garassino, S. Antonia, A. Spira, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 19432026-04-04 · 16:45 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-631
    M. Reck, M.C. Garassino, E. Winer, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 15992026-04-05 · 13:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-719
    P. Schmid, J. Cortes, S. Modi · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 12202026-04-01 · 19:30 CT · S406
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    S. Peters, H. Rugo, F. Andre · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 16242026-04-02 · 16:45 CT · S406
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    S. Peters, A. Spira, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract TPS80162026-04-05 · 14:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-569 study)
    H. Borghaei, S. Modi · University of Chicago
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 14522026-04-04 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for TNBC: KEYNOTE-285
    S. Tolaney, H. Rugo, N. Rizvi · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 13882026-04-05 · 16:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-170
    J. Brahmer, L. Paz-Ares · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 17742026-04-04 · 16:45 CT · Hall B1
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    C. Saura, P. Schmid, A. Spira, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  21. Abstract TPS80202026-04-03 · 21:00 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-710
    T. Mok, P. Schmid · Chinese University of Hong Kong
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract TPS80212026-04-04 · 16:30 CT · Arie Crown Theater
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    H. Borghaei, C. Saura, R. Herbst · Dana-Farber Cancer Institute
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 19252026-04-04 · 18:00 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-963
    M. Krop, F. Andre, J. Cortes, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 11772026-04-03 · 13:00 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-355 study)
    C. Robert, F. Andre, J. Cortes, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  25. Abstract 15892026-04-02 · 13:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-447
    T. Mok, M. Reck, J. Cortes · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 12842026-04-03 · 20:15 CT · Arie Crown Theater
    PALOMA-649: Ibrance (palbociclib) maintenance in HR+ breast cancer
    M.C. Garassino, S. Modi · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract LBA4026LBA2026-04-04 · 14:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-386
    S. Antonia, C. Robert, N. Rizvi · Cleveland Clinic
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  28. Abstract LBA4027LBA2026-04-04 · 13:30 CT · S100A
    MONALEESA-276: Kisqali (ribociclib) 2L in HR+ breast cancer
    M.C. Garassino, L. Paz-Ares · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract LBA4028LBA2026-04-01 · 18:30 CT · E450
    DESTINY-Breast-869: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    S. Antonia, L. Paz-Ares, G. Curigliano · National Cancer Center Japan
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract LBA4029LBA2026-04-01 · 20:30 CT · Hall B1
    MONALEESA-85: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    S. Modi, M.C. Garassino · Karolinska Institute
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  31. Abstract 11082026-04-03 · 15:15 CT · S406
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-943
    S. Peters, J. Brahmer, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 11032026-04-04 · 20:15 CT · S100A
    MONARCH-579: Verzenio (abemaciclib) 1L in HR+ breast cancer
    N. Rizvi, S. Modi, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 17122026-04-02 · 18:45 CT · E450
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-787
    S. Peters, G. Curigliano · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 16312026-04-05 · 13:45 CT · Arie Crown Theater
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    M. Krop, L. Paz-Ares, N. Rizvi · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 18992026-04-03 · 20:30 CT · Hall B1
    MONALEESA-109: Kisqali (ribociclib) 1L in HR+ breast cancer
    P. Schmid, S. Antonia, M. Reck, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 17112026-04-02 · 21:00 CT · Arie Crown Theater
    MONALEESA-420: Kisqali (ribociclib) maintenance in HR+ breast cancer
    H. Rugo, E. Winer · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 14202026-04-03 · 14:45 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-738
    T. Mok, P. Schmid, J. Brahmer, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract e120372026-04-02 · 20:45 CT · S100A
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-517
    H. Borghaei, P. Schmid, A. Spira · Stanford Cancer Institute
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  39. Abstract 10012026-04-02 · 19:15 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-817
    C. Saura, S. Peters, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 10502026-04-03 · 14:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-211
    L. Paz-Ares, S. Modi · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 10262026-04-05 · 16:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-306 study)
    T. Mok, P. Schmid · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 13352026-04-01 · 15:30 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-517 study)
    C. Saura, G. Curigliano · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  43. Abstract 14862026-04-05 · 14:30 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-234 study)
    R. Herbst, S. Antonia, S. Tolaney · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 19552026-04-05 · 15:30 CT · S100A
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-668
    M. Reck, S. Modi · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 14652026-04-05 · 14:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-329
    G. Curigliano, H. Borghaei, E. Winer · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 13222026-04-01 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-505 study)
    S. Modi, T. Mok, H. Borghaei · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 14372026-04-04 · 18:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-474 study)
    J. Cortes, M.C. Garassino · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  48. Abstract 18742026-04-02 · 14:30 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-183 study)
    J. Cortes, P. Schmid, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 10312026-04-05 · 20:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-870
    H. Borghaei, T. Mok, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 15052026-04-03 · 20:00 CT · E450
    OlympiA-281: Lynparza (olaparib) 2L in HR+ breast cancer
    M. Reck, R. Herbst, E. Winer · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 17912026-04-01 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-81
    R. Herbst, E. Winer, H. Rugo, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract 15642026-04-05 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-100 study)
    P. Schmid, S. Modi, G. Curigliano · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 14472026-04-01 · 16:30 CT · E450
    MONARCH-985: Verzenio (abemaciclib) 1L in HR+ breast cancer
    J. Brahmer, N. Rizvi, M.C. Garassino, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract e120532026-04-02 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-232 study)
    G. Curigliano, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  55. Abstract 12792026-04-01 · 13:15 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-225
    A. Spira, J. Brahmer, C. Saura, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 12792026-04-04 · 21:00 CT · S100A
    IMpower-182: Tecentriq (atezolizumab) 2L in TNBC
    P. Schmid, H. Rugo · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  57. Abstract 17042026-04-04 · 20:45 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-76
    M. Krop, S. Modi, N. Rizvi · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 12172026-04-04 · 16:15 CT · S406
    MONARCH-43: Verzenio (abemaciclib) 2L in HR+ breast cancer
    H. Borghaei, S. Antonia · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 13682026-04-05 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-321 study)
    S. Modi, S. Tolaney, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract e120592026-04-05 · 20:15 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-589
    S. Tolaney, T. Mok, M.C. Garassino, et al. · Mayo Clinic
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  61. Abstract 14192026-04-02 · 15:00 CT · S406
    IMpower-11: Tecentriq (atezolizumab) adjuvant in TNBC
    H. Borghaei, M. Krop, S. Peters, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 16112026-04-02 · 15:30 CT · E450
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-78
    J. Brahmer, M.C. Garassino, J. Cortes, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  63. Abstract 17162026-04-05 · 13:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with TNBC
    H. Borghaei, E. Winer, T. Mok · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  64. Abstract 18932026-04-03 · 16:30 CT · S100A
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    T. Mok, S. Modi, C. Robert, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract LBA4064LBA2026-04-03 · 20:15 CT · S100A
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-835 study)
    P. Schmid, S. Antonia · MD Anderson Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 14382026-04-04 · 14:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-294 study)
    R. Herbst, G. Curigliano · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  67. Abstract 17422026-04-02 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-984
    S. Peters, E. Winer · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  68. Abstract 17122026-04-05 · 15:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-289 study)
    M. Reck, S. Peters, H. Borghaei · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 11912026-04-02 · 15:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-209
    H. Borghaei, E. Winer · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  70. Abstract 13842026-04-02 · 19:30 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-612 study)
    P. Schmid, J. Cortes, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract 14192026-04-04 · 18:15 CT · S406
    ASCENT-599: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    S. Peters, H. Rugo · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  72. Abstract 15882026-04-04 · 16:15 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-429
    S. Antonia, S. Tolaney, R. Herbst, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  73. Abstract 12342026-04-05 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-27 study)
    G. Curigliano, S. Peters, E. Winer · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  74. Abstract 12462026-04-04 · 21:00 CT · S100A
    MONARCH-132: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    G. Curigliano, H. Rugo, T. Mok · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract LBA4074LBA2026-04-02 · 18:30 CT · S406
    MONALEESA-373: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    F. Andre, A. Spira, S. Modi, et al. · Institut Gustave Roussy
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 15522026-04-05 · 14:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-45 study)
    P. Schmid, J. Cortes, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 12422026-04-01 · 13:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-740
    S. Modi, E. Winer, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 19782026-04-03 · 19:15 CT · S406
    ASCENT-760: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    S. Antonia, H. Rugo, C. Robert, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  79. Abstract 15562026-04-02 · 20:45 CT · E450
    IMpower-958: Tecentriq (atezolizumab) neoadjuvant in TNBC
    J. Brahmer, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 18362026-04-02 · 19:30 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-128
    G. Curigliano, C. Saura, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  81. Abstract 12032026-04-02 · 15:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-390
    L. Paz-Ares, S. Modi, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 12192026-04-05 · 19:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-831
    S. Modi, J. Cortes, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 14822026-04-02 · 16:00 CT · Hall B1
    PALOMA-898: Ibrance (palbociclib) 1L in HR+ breast cancer
    L. Paz-Ares, C. Robert · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 15692026-04-02 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-744 study)
    R. Herbst, J. Brahmer, M.C. Garassino · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 11272026-04-04 · 13:45 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    H. Rugo, P. Schmid, E. Winer, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  86. Abstract 19202026-04-05 · 16:00 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-351
    F. Andre, G. Curigliano, L. Paz-Ares · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 15722026-04-01 · 21:00 CT · Arie Crown Theater
    MONALEESA-143: Kisqali (ribociclib) 2L in HR+ breast cancer
    L. Paz-Ares, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  88. Abstract 10262026-04-04 · 14:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-433
    C. Robert, S. Modi, M. Krop, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 14342026-04-01 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-819 study)
    R. Herbst, L. Paz-Ares, C. Saura · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 11332026-04-03 · 19:15 CT · E450
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-986
    E. Winer, J. Cortes · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 14162026-04-04 · 13:45 CT · S406
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-449 study)
    S. Tolaney, H. Rugo, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 12292026-04-01 · 14:30 CT · S406
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-407
    F. Andre, L. Paz-Ares, J. Cortes, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  93. Abstract 18772026-04-02 · 15:30 CT · S406
    DESTINY-Breast-99: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    M. Reck, M.C. Garassino, L. Paz-Ares · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 18102026-04-02 · 16:00 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-921
    S. Tolaney, J. Cortes, F. Andre · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 16122026-04-02 · 13:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-74 study)
    L. Paz-Ares, P. Schmid · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  96. Abstract 13352026-04-01 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-8 study)
    J. Brahmer, H. Rugo, C. Robert, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  97. Abstract 18622026-04-04 · 14:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-67
    E. Winer, N. Rizvi, H. Rugo · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 18642026-04-01 · 15:30 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-360 study)
    C. Saura, T. Mok · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 11302026-04-02 · 18:00 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    C. Saura, P. Schmid, R. Herbst, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 19592026-04-01 · 13:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-837
    R. Herbst, S. Tolaney, G. Curigliano · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  101. Abstract 18822026-04-01 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-790
    S. Peters, S. Tolaney, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 12692026-04-02 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-62 study)
    N. Rizvi, C. Robert, A. Spira, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 17162026-04-03 · 15:30 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-813 study)
    S. Peters, F. Andre, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract LBA4103LBA2026-04-04 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-381
    H. Rugo, F. Andre, T. Mok · Mayo Clinic
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  105. Abstract 19292026-04-03 · 13:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-638
    R. Herbst, T. Mok, J. Cortes, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 12782026-04-04 · 14:30 CT · S406
    MONARCH-193: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    S. Tolaney, E. Winer, T. Mok, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 11162026-04-04 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-943
    S. Tolaney, C. Saura, P. Schmid · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  108. Abstract 11992026-04-05 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-18
    J. Brahmer, J. Cortes, G. Curigliano · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract LBA4108LBA2026-04-03 · 13:45 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-753
    L. Paz-Ares, C. Saura · National Cancer Center Japan
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  110. Abstract 16022026-04-03 · 18:00 CT · Hall B1
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-568
    S. Peters, S. Antonia, T. Mok, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 11652026-04-01 · 13:00 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-435
    M. Krop, H. Borghaei, S. Tolaney, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 11832026-04-04 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Enhertu 1L for HR+ breast cancer: DESTINY-Breast-954
    E. Winer, C. Saura, M. Reck · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 13362026-04-02 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-802 study)
    T. Mok, N. Rizvi, C. Saura, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 15112026-04-04 · 13:45 CT · Hall B1
    PALOMA-995: Ibrance (palbociclib) maintenance in HR+ breast cancer
    S. Peters, M. Krop, S. Tolaney, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  115. Abstract 11982026-04-01 · 15:45 CT · S406
    Long-term follow-up of Tecentriq 2L for TNBC: IMpower-929
    M. Krop, C. Robert, F. Andre, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 13732026-04-04 · 14:45 CT · E450
    MONARCH-724: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    F. Andre, S. Peters, P. Schmid · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  117. Abstract 13142026-04-05 · 19:30 CT · E450
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-332
    G. Curigliano, N. Rizvi, M.C. Garassino, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  118. Abstract 18462026-04-04 · 21:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-194 study)
    T. Mok, A. Spira, H. Borghaei · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  119. Abstract e121182026-04-01 · 15:45 CT · Hall B1
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-925
    C. Robert, A. Spira, C. Saura, et al. · Peter MacCallum Cancer Centre
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  120. Abstract 16192026-04-03 · 20:00 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-879
    E. Winer, S. Modi, S. Tolaney, et al. · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract LBA4120LBA2026-04-01 · 16:45 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-683
    S. Peters, J. Brahmer, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  122. Abstract 19692026-04-02 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-373 study)
    G. Curigliano, S. Tolaney, T. Mok, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  123. Abstract 14502026-04-05 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-467 study)
    R. Herbst, M. Krop, J. Cortes, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 15232026-04-04 · 14:30 CT · S406
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-378
    C. Saura, S. Peters · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  125. Abstract TPS81242026-04-02 · 13:30 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-783 study)
    S. Tolaney, G. Curigliano · Institut Gustave Roussy
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 13112026-04-04 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-410
    J. Cortes, M.C. Garassino, M. Krop, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 16012026-04-02 · 14:30 CT · Hall B1
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-264
    C. Robert, G. Curigliano · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 11992026-04-04 · 16:00 CT · E450
    PALOMA-746: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    E. Winer, L. Paz-Ares, C. Saura, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 10702026-04-04 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-818 study)
    H. Rugo, M. Reck, M.C. Garassino, et al. · University of Chicago
    Education SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 18192026-04-03 · 18:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-688
    S. Antonia, T. Mok, M. Reck, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 10552026-04-03 · 18:15 CT · Arie Crown Theater
    MONALEESA-801: Kisqali (ribociclib) 2L in HR+ breast cancer
    E. Winer, H. Borghaei, M. Reck, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  132. Abstract 15372026-04-04 · 16:15 CT · Arie Crown Theater
    MONARCH-137: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    C. Robert, M. Krop · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract LBA4132LBA2026-04-03 · 15:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-513
    C. Saura, H. Rugo, H. Borghaei, et al. · Royal Marsden Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  134. Abstract 12622026-04-05 · 16:15 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-65
    A. Spira, L. Paz-Ares, C. Robert · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 11982026-04-02 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-282 study)
    R. Herbst, T. Mok, J. Cortes, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract 18082026-04-02 · 14:45 CT · S406
    MONARCH-694: Verzenio (abemaciclib) 2L in HR+ breast cancer
    S. Tolaney, P. Schmid, H. Rugo · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  137. Abstract 11252026-04-01 · 16:00 CT · Hall B1
    MONARCH-867: Verzenio (abemaciclib) 1L in HR+ breast cancer
    F. Andre, A. Spira, P. Schmid, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 11202026-04-01 · 20:00 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    G. Curigliano, M. Krop, L. Paz-Ares, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 18022026-04-04 · 18:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-771
    H. Borghaei, H. Rugo · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  140. Abstract 13462026-04-01 · 19:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-934 study)
    J. Brahmer, S. Antonia, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 12162026-04-03 · 20:30 CT · S406
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-284
    H. Borghaei, G. Curigliano · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 11452026-04-05 · 14:15 CT · Hall B1
    IMpower-114: Tecentriq (atezolizumab) 2L in TNBC
    C. Saura, H. Borghaei, S. Antonia · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  143. Abstract LBA4142LBA2026-04-03 · 16:45 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    E. Winer, G. Curigliano, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  144. Abstract TPS81432026-04-01 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-616 study)
    M. Krop, S. Tolaney, M. Reck, et al. · Dana-Farber Cancer Institute
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  145. Abstract 15072026-04-02 · 16:45 CT · E450
    PALOMA-648: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    C. Saura, P. Schmid, N. Rizvi · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 13422026-04-03 · 21:45 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-47
    R. Herbst, T. Mok, M. Krop, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  147. Abstract 12502026-04-04 · 15:15 CT · E450
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-578
    M. Krop, G. Curigliano, F. Andre, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 14152026-04-01 · 19:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-631
    F. Andre, R. Herbst, L. Paz-Ares · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 12292026-04-01 · 19:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-407
    E. Winer, S. Tolaney · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 13402026-04-02 · 18:30 CT · S406
    IMpower-345: Tecentriq (atezolizumab) maintenance in TNBC
    N. Rizvi, H. Rugo · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 19772026-04-05 · 21:00 CT · S100A
    MONALEESA-147: Kisqali (ribociclib) maintenance in HR+ breast cancer
    S. Peters, J. Brahmer · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  152. Abstract 14472026-04-02 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-735 study)
    F. Andre, S. Modi · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  153. Abstract LBA4152LBA2026-04-01 · 13:30 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-710
    S. Peters, J. Cortes, E. Winer, et al. · University of Chicago
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  154. Abstract 11022026-04-02 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-390
    C. Saura, G. Curigliano, M. Reck, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 15062026-04-05 · 14:45 CT · S100A
    KEYNOTE-671: Keytruda (pembrolizumab) 3L+ in TNBC
    S. Tolaney, H. Borghaei, M.C. Garassino, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  156. Abstract 14452026-04-01 · 14:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-64
    C. Saura, G. Curigliano, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  157. Abstract 12932026-04-04 · 15:15 CT · Hall B1
    PALOMA-73: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    F. Andre, C. Robert, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 16982026-04-01 · 21:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-111
    J. Brahmer, C. Saura, F. Andre, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 13072026-04-05 · 19:15 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-624 study)
    H. Borghaei, S. Tolaney, M. Reck, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  160. Abstract 17792026-04-04 · 20:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-639 study)
    J. Cortes, S. Antonia, C. Robert · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  161. Abstract 15762026-04-03 · 19:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-74
    S. Antonia, M.C. Garassino · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  162. Abstract 14582026-04-04 · 13:45 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-510
    S. Antonia, P. Schmid, J. Brahmer · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 13452026-04-03 · 13:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-510 study)
    S. Modi, S. Antonia, E. Winer, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 17062026-04-05 · 13:15 CT · S406
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-880
    H. Borghaei, J. Brahmer, S. Peters · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 18742026-04-02 · 13:00 CT · Hall B1
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-303
    R. Herbst, F. Andre, L. Paz-Ares, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  166. Abstract 13522026-04-05 · 15:15 CT · Hall B1
    PALOMA-110: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    H. Rugo, S. Tolaney · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 10242026-04-01 · 20:30 CT · Arie Crown Theater
    MONALEESA-64: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    R. Herbst, T. Mok, J. Cortes, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  168. Abstract TPS81672026-04-04 · 19:45 CT · S100A
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-526
    G. Curigliano, A. Spira, C. Robert · Cleveland Clinic
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  169. Abstract 16202026-04-04 · 18:00 CT · S100A
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-145
    N. Rizvi, S. Antonia, L. Paz-Ares, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 11062026-04-01 · 20:00 CT · S100A
    PALOMA-60: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    J. Brahmer, S. Peters, R. Herbst, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 14792026-04-01 · 13:00 CT · S100A
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-270 study)
    R. Herbst, E. Winer, C. Saura, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 10962026-04-05 · 19:00 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-229
    C. Saura, C. Robert, S. Tolaney, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 15032026-04-01 · 13:00 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-831
    H. Rugo, S. Tolaney, G. Curigliano · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 15322026-04-02 · 16:00 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-874
    M. Reck, H. Borghaei, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  175. Abstract 18082026-04-05 · 19:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-849 study)
    P. Schmid, T. Mok, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract LBA4175LBA2026-04-01 · 19:30 CT · S100A
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-751 study)
    S. Modi, G. Curigliano, C. Robert, et al. · Mayo Clinic
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  177. Abstract 10372026-04-02 · 20:00 CT · Hall B1
    MONARCH-509: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    C. Robert, H. Rugo, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 19162026-04-05 · 14:30 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-196
    S. Modi, G. Curigliano, H. Rugo · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 15432026-04-02 · 18:15 CT · Hall B1
    MONARCH-120: Verzenio (abemaciclib) 2L in HR+ breast cancer
    J. Cortes, M. Reck, R. Herbst · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 17272026-04-01 · 15:00 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-890
    S. Tolaney, M. Reck, F. Andre, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 10372026-04-01 · 16:30 CT · S406
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-860
    R. Herbst, M. Krop, M.C. Garassino, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 19232026-04-02 · 20:15 CT · Hall B1
    MONALEESA-503: Kisqali (ribociclib) 1L in HR+ breast cancer
    F. Andre, S. Tolaney · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 19262026-04-02 · 14:45 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-444
    S. Antonia, A. Spira, C. Robert, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  184. Abstract 12062026-04-05 · 21:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-122
    H. Rugo, C. Saura, E. Winer · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  185. Abstract e121842026-04-05 · 14:30 CT · E450
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-860
    N. Rizvi, S. Tolaney, A. Spira, et al. · University of Chicago
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  186. Abstract 16542026-04-02 · 21:00 CT · Hall B1
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-495
    A. Spira, C. Saura, F. Andre · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  187. Abstract 19312026-04-03 · 14:00 CT · S100A
    IMpower-981: Tecentriq (atezolizumab) 3L+ in TNBC
    R. Herbst, F. Andre, S. Antonia, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 19462026-04-04 · 18:30 CT · S100A
    PALOMA-716: Ibrance (palbociclib) 2L in HR+ breast cancer
    J. Brahmer, T. Mok, S. Peters · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  189. Abstract 12982026-04-04 · 20:00 CT · Arie Crown Theater
    OlympiA-635: Lynparza (olaparib) 3L+ in HR+ breast cancer
    L. Paz-Ares, E. Winer · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 11702026-04-02 · 13:30 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-787
    J. Cortes, S. Antonia, S. Peters, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  191. Abstract 13692026-04-01 · 21:00 CT · S406
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-769
    S. Modi, F. Andre · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  192. Abstract 12582026-04-05 · 14:15 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-96
    C. Saura, F. Andre, G. Curigliano, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  193. Abstract 11152026-04-05 · 20:45 CT · S406
    MONALEESA-790: Kisqali (ribociclib) 1L in HR+ breast cancer
    L. Paz-Ares, H. Borghaei, N. Rizvi, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  194. Abstract 11582026-04-01 · 16:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-697 study)
    C. Robert, J. Brahmer, H. Rugo, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  195. Abstract 13862026-04-04 · 18:00 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-668
    S. Tolaney, P. Schmid, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  196. Abstract 11962026-04-05 · 15:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-710
    L. Paz-Ares, H. Rugo, M. Reck, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  197. Abstract 12112026-04-01 · 16:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-642 study)
    G. Curigliano, R. Herbst · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  198. Abstract 13422026-04-02 · 20:15 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-186
    J. Cortes, G. Curigliano, S. Modi · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  199. Abstract 14002026-04-01 · 15:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-976
    J. Cortes, P. Schmid, N. Rizvi, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract LBA4199LBA2026-04-02 · 14:15 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-317
    H. Borghaei, M. Krop · University of Chicago
    Plenary SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.